4D Molecular Therapeutics Inc (FDMT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $689.52M
Last updated: Nov 17, 2026 at 11:06 AM ET
4D Molecular Therapeutics Inc (FDMT) Earnings: Report Dates and Results
4D Molecular Therapeutics (FDMT) is expected to report earnings on Mar 16, 2027. In the quarter ended Sep 30, 2026, 4D Molecular Therapeutics reported EPS of -$1.08, below the -$1.04 estimate. It beat the EPS estimate in 1 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
FDMT has an expected report date of Mar 16, 2027.
Earnings History
Of the 25 quarters below that had an estimate, FDMT beat 9, missed 13 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $4.14M, up 4500.0% from $90000 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.08 | -$1.04 | -$1.10 - -$0.99 | -3.85% | Miss | N/A | 11 | 1 up, 1 down | Nov 12, 2026 | $4.14M |
| Jun 30, 2026 | -$1.04 | -$1.04 | -$1.10 - -$0.89 | 0.00% | In line | N/A | 9 | 0 up, 1 down | Aug 13, 2026 | $3.78M |
| Mar 31, 2026 | -$1.01 | -$1.00 | -$1.32 - -$0.84 | -1.00% | Miss | N/A | 9 | 0 up, 2 down | May 7, 2026 | $3.05M |
| Dec 31, 2025 | $0.43 | -$0.53 | -$1.05 - $0.42 | +180.83% | Beat | N/A | 10 | 8 up, 1 down | Mar 18, 2026 | $85.21M |
| Sep 30, 2025 | -$1.01 | -$0.98 | -$1.08 - -$0.80 | -3.06% | Miss | N/A | 10 | 2 up, 8 down | Nov 10, 2025 | $90000 |
| Jun 30, 2025 | -$0.98 | -$0.69 | -$1.04 - $0.95 | -42.03% | Miss | N/A | 10 | 0 up, 1 down | Aug 11, 2025 | $15000 |
| Mar 31, 2025 | -$0.86 | -$0.86 | -$1.05 - -$0.69 | 0.00% | In line | N/A | 9 | 0 up, 1 down | May 8, 2025 | N/A |
| Dec 31, 2024 | -$0.90 | -$0.84 | -$1.16 - -$0.57 | -7.41% | Miss | N/A | 10 | 2 up, 2 down | Feb 28, 2025 | $1000 |
| Sep 30, 2024 | -$0.79 | -$0.70 | -$0.80 - -$0.63 | -12.86% | Miss | N/A | 8 | 0 up, 0 down | Nov 13, 2024 | N/A |
| Jun 30, 2024 | -$0.63 | -$0.71 | -$0.81 - -$0.61 | +11.27% | Beat | N/A | 9 | 0 up, 0 down | Aug 8, 2024 | N/A |
| Mar 31, 2024 | -$0.66 | -$0.76 | -$0.84 - -$0.68 | +13.16% | Beat | N/A | 6 | 0 up, 0 down | May 9, 2024 | N/A |
| Dec 31, 2023 | -$0.75 | -$0.74 | -$0.87 - -$0.39 | -1.35% | Miss | N/A | 8 | 2 up, 0 down | Feb 29, 2024 | $519000 |
| Sep 30, 2023 | -$0.24 | -$0.60 | -$0.87 - -$0.27 | +60.00% | Beat | N/A | 6 | 0 up, 0 down | Nov 9, 2023 | $20.20M |
| Jun 30, 2023 | -$0.77 | -$0.77 | -$0.89 - -$0.72 | 0.00% | In line | N/A | 5 | 0 up, 0 down | Aug 9, 2023 | N/A |
| Mar 31, 2023 | -$0.88 | -$0.90 | -$1.00 - -$0.78 | +2.22% | Beat | N/A | 5 | 0 up, 0 down | May 10, 2023 | N/A |
| Dec 31, 2022 | -$0.84 | -$0.79 | -$0.95 - -$0.48 | -6.33% | Miss | N/A | 5 | 0 up, 0 down | Mar 15, 2023 | $1.25M |
| Sep 30, 2022 | -$0.79 | -$0.91 | -$1.11 - -$0.79 | +13.19% | Beat | N/A | 4 | 0 up, 0 down | Nov 8, 2022 | $500000 |
| Jun 30, 2022 | -$0.87 | -$0.85 | -$1.07 - -$0.69 | -2.35% | Miss | N/A | 4 | 0 up, 0 down | Aug 11, 2022 | $162000 |
| Mar 31, 2022 | -$0.82 | -$0.77 | -$0.98 - -$0.68 | -6.49% | Miss | N/A | 3 | 0 up, 0 down | May 12, 2022 | $1.22M |
| Dec 31, 2021 | -$0.85 | -$0.86 | -$0.94 - -$0.79 | +1.16% | Beat | N/A | 3 | 0 up, 0 down | Mar 28, 2022 | $92000 |
| Sep 30, 2021 | -$0.82 | -$0.80 | -$0.83 - -$0.78 | -2.50% | Miss | N/A | 2 | N/A | Nov 10, 2021 | $1.37M |
| Jun 30, 2021 | -$0.28 | -$0.68 | -$0.71 - -$0.65 | +58.82% | Beat | N/A | 2 | N/A | Aug 12, 2021 | $14.58M |
| Mar 31, 2021 | -$0.61 | -$1.10 | -$1.10 - -$1.10 | +44.55% | Beat | N/A | 1 | N/A | May 13, 2021 | $2.00M |
| Dec 31, 2020 | -$2.36 | -$0.66 | -$0.66 - -$0.66 | -257.58% | Miss | N/A | 1 | N/A | Mar 25, 2021 | N/A |
| Sep 30, 2020 | -$3.07 | -$0.40 | N/A | -667.50% | Miss | N/A | N/A | N/A | Dec 16, 2020 | $7.42M |
| Sep 30, 2019 | -$3.12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2019 | $540000 |
| Jun 30, 2019 | -$1.82 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2019 | $2.21M |
| Mar 31, 2019 | -$1.61 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2019 | $2.21M |
| Dec 31, 2018 | -$1.61 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2019 | $4.53M |
| Sep 30, 2018 | -$0.43 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2018 | $4.53M |
| Jun 30, 2018 | -$0.43 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2018 | $2.53M |
| Mar 31, 2018 | -$0.52 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2018 | $2.53M |
| Dec 31, 2017 | -$0.52 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2018 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.42, after -$2.98 the year before. It was -$0.52 for the year ended Dec 31, 2017, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.42 | N/A |
| Dec 31, 2024 | -$2.98 | N/A |
| Dec 31, 2023 | -$2.64 | N/A |
| Dec 31, 2022 | -$3.32 | N/A |
| Dec 31, 2021 | -$2.56 | N/A |
| Dec 31, 2020 | -$11.98 | N/A |
| Dec 31, 2018 | -$2.98 | N/A |
| Dec 31, 2017 | -$0.52 | N/A |
Frequently Asked Questions About FDMT
When is 4D Molecular Therapeutics's next earnings date?
4D Molecular Therapeutics's next earnings report is expected for Mar 16, 2027.
Did FDMT beat earnings estimates last quarter?
No. 4D Molecular Therapeutics reported EPS of -$1.08 for the quarter ended Sep 30, 2026, below the -$1.04 estimate by 3.85%.
What EPS do analysts expect from FDMT next quarter?
The consensus EPS estimate for 4D Molecular Therapeutics for the quarter ending Dec 31, 2026 is -$1.10 from 13 analysts, with estimates from -$1.19 to -$1.00.
How often does FDMT beat earnings estimates?
4D Molecular Therapeutics beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of +15.43%.
FDMT pages: Overview, Earnings, Forecast, Financials, Competitors